SCHEMBL935810

SCHEMBL935810

O=C1Nc2c(Br)cccc2C1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 5/20 0.60
DAO P14920 2/20 0.60
NSD2 O96028 1/20 0.60
BCHE P06276 1/20 0.60
LIG1 P18858 1/20 0.55
ALDH1A1 P00352 1/20 0.52
ALDH2 P05091 1/20 0.52
ALDH3A1 P30838 1/20 0.52
CASP3 P42574 1/20 0.48
CASP2 P42575 1/20 0.48
CASP7 P55210 1/20 0.48
CASP6 P55212 1/20 0.48
CASP8 Q14790 1/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
PIM1 P11309 1/20 0.44
CSNK1A1 P48729 1/20 0.44
CDK5 Q00535 1/20 0.44
ROCK1 Q13464 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29440762 1.00 CES1 (0.60) CES1DAONSD2BCHELIG1
SCHEMBL31107458 0.80 PIM1 (0.42) CES1DAONSD2BCHELIG1
SCHEMBL20535074 0.76 TGM2 (0.42) CES1DAONSD2BCHELIG1
SCHEMBL31244367 0.75 CES1 (0.60) CES1DAONSD2BCHELIG1
SCHEMBL6845708 0.75 CES1 (0.60) CES1DAONSD2BCHELIG1
SCHEMBL1247382 0.75 CES1 (1.00) CES1DAONSD2BCHELIG1
SCHEMBL5332282 0.75 CES1 (0.60) CES1DAONSD2BCHELIG1
SCHEMBL281604 0.75 CES1 (0.60) CES1DAONSD2BCHELIG1
SCHEMBL505703 0.75 CES1 (0.60) CES1DAONSD2BCHELIG1
SCHEMBL3088689 0.75 DAO (1.00) CES1DAONSD2BCHELIG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114950159-B Preparation method of aromatic polymer separation membrane based on super acid catalysis 南京工业大学 2023-06-06 CN claimed
CN-111187233-B Polysubstituted benzothiazole and derivative and synthesis method thereof 湘潭大学 2023-05-30 CN claimed
CN-114950159-A Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation 南京工业大学 2022-08-30 CN claimed
CN-111574426-A Diamine monomer containing isoindigo structure and black polyimide synthesized from diamine monomer 湘潭大学 2020-08-25 CN claimed
CN-111187233-A Polysubstituted benzothiazole and derivative and synthesis method thereof 湘潭大学 2020-05-22 CN claimed
CN-108558782-A The amido modified trisubstituted 1,3,5-triazine and preparation method thereof in ortho position 武汉工程大学 2018-09-21 CN claimed
CN-102690226-A Multi-nitrogen substituted isatin derivative and synthetic method of multi-nitrogen substituted isatin derivative UNIV GUANGDONG TECHNOLOGY 2012-09-26 CN claimed
US-20070130702-A1 Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative L'OREAL S.A. 2007-06-14 US claimed
US-7204857-B1 Dyeing method using a specific active methylene compound and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative L'OREAL S.A. (FR) 2007-04-17 US claimed
US-6635090-B1 Dyeing method using a specific cationic derivative and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative L'OREAL, S.A. (FR) 2003-10-21 US claimed
US-6458168-B1 Hair dyeing method using an aliphatic cationic amine and compound chosen from an aldehyde, a ketone, a quinone, a di-imino-isoindoline, and a 3-aminoisoindolone derivative L'OREAL S.A. (FR) 2002-10-01 US claimed
US-6451067-B1 HAIR DYE MIXTURE L'OREAL S.A. (FR) 2002-09-17 US claimed
US-12637447-B2 Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective mcl-1 inhibitors and as dual mcl-1/bcl-2 inhibitors UNIVERSITY OF MARYLAND, BALTIMORE (US) 2026-05-26 US disclosed
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO ARVINAS OPERATIONS, INC. (US) 2026-04-23 US disclosed
EP-4724430-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE Flagship Pioneering Innovations VI, LLC (US) 2026-04-15 EP disclosed
US-12589156-B2 Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) ARVINAS OPERATIONS, INC. (US) 2026-03-31 US disclosed
US-4886886-A FORMED FROM TRIFLUOROACETANILIDE IN MULTISTEP PROCEDURE AMERICAN HOME PRODUCTS CORPORATION (US) 1989-12-12 US disclosed
US-4785015-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1988-11-15 US disclosed
EP-0279548-A1 Substituted 1,3,4,9-tetrahydropyrano [3,4-b] indole-1-acetic acids AMERICAN HOME PRODUCTS CORPORATION (US) 1988-08-24 EP disclosed
US-4185009-A Branched, high-molecular weight thermoplastic polycarbonates BAYER AKTIENGESELLSCHAFT (DE) 1980-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070130702-A1 Dyeing process using a specific compound containing active methylene and a compound chosen from a specific aldehyde, a specific ketone, a quinone and a diiminoisoindoline or 3-aminoisoindolone derivative KRT18, NDUFB5, NDUFB7 CES1 3158/4885DAO 161/4885NSD2 872/4885
US-12637447-B2 Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective mcl-1 inhibitors and as dual mcl-1/bcl-2 inhibitors MCL1, BCL2L1, BCL2L2 CES1 1048/4885DAO 983/4885NSD2 45/4885
US-12589156-B2 Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) LRRK2, SNCA, PARK7 CES1 4823/4885DAO 3330/4885NSD2 1027/4885
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO KRAS, CRBN, HRAS CES1 1326/4885DAO 885/4885NSD2 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.